Eisai strengthened Pariet's sales, collaborated with Yuhan

Following Pariet 5mg, co-promotion of Pariet 10-20mg will be expanded starting this month

Growth stagnating from 2018, Efforts to expand the lineup such as expanding the lineup and dealing with domestic companies

Eisai strengthened the collaboration of Pariet (Rabeprazole) with a domestic company of PPI.

 

The joint sales were expanded to Pariet 10·20mg following low-dose Pariet 5mg.

 

According to the pharmaceutical industry on the 3rd, Yuhan recently signed a joint sale contract with Eisai for Pariet 10·20mg, and started supplying the product from this month.

 

Yuhan will focus on hospitals and clinics, and co-promotions will be held by the two companies in general and university hospitals.

 

Eisai signed a partnership with Yuhan earlier this year to sell low-dose Pariet 5mg.

 

This is the first co-promotion with a domestic company.

 

After that, the two companies expanded the contract to Pariet 10·20mg.

 

Pariet is a representative PPI product developed by Eisai and launched in Korea in 2000.

 

At that time, it was leading the PPI market with a high market share, but performance has slowed in recent years due to intensifying competition such as PPI formulations and generics.

 

Based on UBIST, Pariet's outpatient prescriptions amounted to ₩6.3 billion in 2015, ₩8 billion in 2016, and ₩12.4 billion in 2017, showing a double-digit growth rate from the previous year.

 

The stagnation of earnings began in 2018.

 

In 2018, it reached ₩13 billion, an increase of only 5.2% from the previous year, and in 2019, it increased slightly to ₩13.3 billion.

 

This year, the aftermath of COVID-19 was added.

 

Until the third quarter, the cumulative prescription amount was ₩7.9 billion, down about 20% from the same period last year.

 

Eisai, which had sold exclusively after ending the joint sales contract with Janssen in 2015, launched aggressive marketing to increase sales.

 

After strengthening the Pariet lineup last year, it signed a co-promotion contract with Yuhan this year.

 

Pariet 5mg introduced in Korea in September of last year.

 

Pariet 5mg is the lowest dose among PPI and released in Korea.

 

Low-dose Pariet is receiving a positive response from medical staff who prescribe long-term prescriptions.

 

An official from Eisai said, "As Yuhan's strong sales power was added, it was determined that the synergy effect was clear." He also explained, "The marketing was not active due to COVID-19 incident right after the contract, but sales of Pariet will be expanded."